Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329381 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00329381: Completed Phase 4 study, sponsored by University of Mississippi Medical Center.
NCT00329381 is a Phase 4 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00329381, a Phase 4 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab(administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).
Interventions
- DRUG Xolair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-10 |
| Phase | Phase 4 |
What the finished NCT00329381 record still lists
NCT00329381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Xolair is the first listed.
NCT00329381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00329381 about?
NCT00329381 is a clinical study titled "Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy". In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab(administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administe...
What is the current status of trial NCT00329381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2006-05. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00329381?
The interventions under investigation include: Xolair (DRUG).
Who is sponsoring clinical trial NCT00329381?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00329381's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia